Zobraziť v EDS

Prognostic importance of CD47 expression on survival of colorectal cancer.

Uložené v:
Podrobná bibliografia
Názov: Prognostic importance of CD47 expression on survival of colorectal cancer.
Autori: Aktepe, Oktay Halit, Kurtulan, Olcay, Dama, Pinar Ezgi, Yildirim, Eda Caliskan, Terzi, Aytac, Kalyoncu, Simin Alara, Atag, Elif, Yavuzsen, Tugba, Uner, Meral, Karaoglu, Aziz, Yalcin, Suayib
Zdroj: BMC Gastroenterology; 10/24/2025, Vol. 25 Issue 1, p1-8, 8p
Predmety: CD47 antigen, COLORECTAL cancer, PROGNOSIS, OVERALL survival, COLECTOMY, LYMPH nodes, BIOLOGICALS, IMMUNOHISTOCHEMISTRY
Abstrakt: Background: The exact value of cluster of differentiation 47 (CD47), known as the "don't eat me" signal, in colorectal cancer (CRC) has not been clearly revealed. Thus, we investigated the impact of its expression on the overall survival (OS) of CRC patients who underwent colectomy. Methods: Ninety-eight CRC patients were included. The patient population was grouped into two categories based on the median value of CD47 expression examined with immunohistochemistry: negative (< median) and positive (≥ median). The estimation of OS was executed with the Kaplan-Meier method, and the difference in prognostic groups was tested with the log-rank test. The association of CD47 with OS was examined with univariate and multivariate Cox regression models. Results: CD47 expression was recorded in 56.1% of CRC patients. Among the clinicopathological variables, the only significant difference between the prognostic groups was the presence of lymph node involvement (p = 0.005). The OS of patients with CD47 expression was lower than those with no CD47 expression (39.3 months vs. not reached, p = 0.001, respectively). Additionally, in metastatic CRC patients treated with biologic agents, patients with CD47 expression had numerically inferior OS times than those without CD47 expression (37 months vs. 58.5 months, p = 0.05, respectively). Our multivariate analysis showed that CD47 was an independent prognostic factor associated with OS in this cohort (HR: 2.142, p = 0.006). Conclusion: Our study suggests that CD47 may serve as a potential prognostic marker and a promising therapeutic target for anti-CD47–based treatments in CRC. [ABSTRACT FROM AUTHOR]
Copyright of BMC Gastroenterology is the property of BioMed Central and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Databáza: Complementary Index
Popis
Abstrakt:Background: The exact value of cluster of differentiation 47 (CD47), known as the "don't eat me" signal, in colorectal cancer (CRC) has not been clearly revealed. Thus, we investigated the impact of its expression on the overall survival (OS) of CRC patients who underwent colectomy. Methods: Ninety-eight CRC patients were included. The patient population was grouped into two categories based on the median value of CD47 expression examined with immunohistochemistry: negative (< median) and positive (≥ median). The estimation of OS was executed with the Kaplan-Meier method, and the difference in prognostic groups was tested with the log-rank test. The association of CD47 with OS was examined with univariate and multivariate Cox regression models. Results: CD47 expression was recorded in 56.1% of CRC patients. Among the clinicopathological variables, the only significant difference between the prognostic groups was the presence of lymph node involvement (p = 0.005). The OS of patients with CD47 expression was lower than those with no CD47 expression (39.3 months vs. not reached, p = 0.001, respectively). Additionally, in metastatic CRC patients treated with biologic agents, patients with CD47 expression had numerically inferior OS times than those without CD47 expression (37 months vs. 58.5 months, p = 0.05, respectively). Our multivariate analysis showed that CD47 was an independent prognostic factor associated with OS in this cohort (HR: 2.142, p = 0.006). Conclusion: Our study suggests that CD47 may serve as a potential prognostic marker and a promising therapeutic target for anti-CD47–based treatments in CRC. [ABSTRACT FROM AUTHOR]
ISSN:1471230X
DOI:10.1186/s12876-025-04371-3